Kyung Hee University and ST Pharm Co. Ltd. have patented ergostenol derivatives described as potentially useful for the treatment of inflammatory bowel disease (IBD).

Macrocyclic compounds acting as induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors have been reported in a Zeno Management Inc. patent. They are reported to be potentially useful for the treatment of cancer.

Research at Schroedinger Inc. has led to the development of son of sevenless homolog 1 (SOS1) and SOS1/GTPase KRAS (G12C mutant) interaction inhibitors potentially useful for the treatment of cancer.

Orexin OX2 receptor agonists have been described in a recent Sumitomo Pharma Co. Ltd. patent as potentially useful for the treatment of hypersomnia, narcolepsy and sleep apnea, among others.

Pardes Biosciences Inc. has patented 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors (particularly HCoV-229E virus and/or SARS-CoV-2 Mpro inhibitors). They are reported to be potentially useful for the treatment of SARS-CoV-2 infections (COVID-19).

A recent Epigen Biosciences Inc. patent describes ribosomal protein S6 kinase β (p70S6K) inhibitors reported to be useful for the treatment of diabetes, autism spectrum disorders, fibrosis, fragile X syndrome, liver diseases and nonalcoholic steatohepatitis (NASH).

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has developed antibody-drug conjugates (ADCs) consisting of 19F6_Hu35V1 antibody covalently linked to a cytotoxic drug through a linker.

Research at Silexon Biotech Co. Ltd. has led to the identification of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, hepatitis B virus, hepatitis C virus and HIV infections.

Several recent patents from Vertex Pharmaceuticals Inc. have disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, Charcot-Marie-tooth disease, cough, urinary incontinence and multiple sclerosis.

An Otsuka Pharmaceutical Co. Ltd. patent describes pyrazolo[1,5-a]pyrimidine lysophosphatidic acid receptor 2 (LPAR2; EDG4) antagonists reported to be useful for the treatment of atopic dermatitis, psoriasis, eczema, scleroderma and pruritus, among others.